Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Cybin Inc (CYBN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cybin's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.370 -0.001    -0.16%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
0.372
+0.002
+0.514%
18:09:29 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 3,692,431
  • Bid/Ask: 0.372 / 0.372
  • Day's Range: 0.352 - 0.380
Cybin 0.370 -0.001 -0.16%

Cybin Inc Company Profile

 
Get an in-depth profile of Cybin Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

50

Equity Type

ORD

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Contact Information

Address 100 King Street West Suite 5600
Toronto, M5X 1C9
Canada
Phone -
Fax -
Web www.cybin.com

Top Executives

Name Age Since Title
Anthony Back - 2021 Member of Clinical Advisory Board
Thomas P. Laughren - 2021 Member of Clinical Advisory Board
Lynn Marie Morski - 2021 Member of Clinical Advisory Board
Maurizio Fava - 2021 Member of Clinical Advisory Board
Paul Glavine 33 2020 Co-Founder, Chief Growth Officer & Director
Eric So 46 2020 Co-Founder, President & Executive Chairman
Eric William Hoskins 62 2020 Independent Director
Grant B. Froese 61 2020 Independent Director
Theresa S. Firestone 68 2021 Lead Independent Director
George Tziras - 2023 Chief Business Officer & Director
Mark A. Lawson 51 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CYBN Comments

Write your thoughts about Cybin Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
nelson Dias
nelson Dias Oct 23, 2023 9:44AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
love this stock it will be in much demand
Reply
1 0
Report
Deb Fisler
Deb Fisler Sep 09, 2022 3:39PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Last week I was way-up on this dog don't bother with it.
Reply
0 0
Report
Deb Fisler
Deb Fisler Sep 06, 2022 4:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Unfortunately little obscure stocks with big potential are at the mercy of greedy skimmers
Reply
0 0
Report
Deb Fisler
Deb Fisler Sep 06, 2022 3:14PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I've seen this pattern before...skimmers...it'll never be the stock that it's capable of being because they skim off the top every time it goes over $1.00 don't bother with this inexpensive one.
Reply
0 0
Report
Hyborian War
HyborianWar Apr 04, 2022 3:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
🍄
Reply
0 0
Report
Dec 08, 2021 9:44PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
http://crweworld.com/article/news-provided-by-business-wire/2225622/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003-for-the-treatment-of-major-depressive-disorder-and-alcohol-usen-disorder
Reply
1 0
Report
Trace Jared
Trace Jared Jan 15, 2021 2:24PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's with the big jump today
Reply
0 0
Report
Trace Jared
Trace Jared Jan 15, 2021 2:23PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what's with the big jump today ?
Reply
0 0
Report
James Almeida Stille
James Almeida Stille Jan 15, 2021 2:23PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Canadian investment bank Stifel GMP has released new research on psychedelics and both $FTRP and $CYBN Their research calls psychedelic medicines a "possible disruptor to legacy treatments" and shares their perspective that there is an "accelerating wave of psychedelic reform." CYBN was given a speculative buy rating and a $5 price target. The report can be found with a quick google search.
Reply
1 1
Report
James Almeida Stille
James Almeida Stille Jan 15, 2021 2:23PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
At this point, I'm not a fan of FTRP due to the fact that its trading on such low daily volume. Also, the Horizon ETF (PSYK) is about to launch and they might have been buying up CYBN on Friday. Not giving advice on what to do. Always do your own DD. Good luck!
Reply
1 0
Report
James Almeida Stille
James Almeida Stille Jan 08, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This one is my favourite companies in this sector at the moment. One of the side effects of psilocybin mushrooms in higher dosages is mild nausea. Their sublingual film drug (psilotonin) which is about to enter phase 2a bypasses the stomach, liver etc. In other words, everyone else is working on pill formulations that have to be digested while these folks seem to have a brilliant product in the making. Anyone else here holding long? If so, what are your reasons for liking this one?
Reply
2 1
Report
Shawn Gauvreau
Shawn Gauvreau Jan 08, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Holding long, MMED is at the fore front in this ground breaking industry. This is just the beginning. I predict this stock to be + $10.00 within two years and + $20.00 after first FDA approval
Reply
0 0
Report
James Almeida Stille
James Almeida Stille Jan 08, 2021 2:49PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Shawn Gauvreau  CYBN is undervalued compared to its peers imo and I have a feeling that people are sleeping on this one. If you haven't read over their investor presentations, I highly recommend going to view them on their website. Keep in mind that these drugs are going to be used in clinics with psychotherapy integration to help the patients find what they really need to take away from their mystical experience in order to heal their depression and regain control of their lives. Just my opinion here, everyone must do their own DD. Good luck!
Reply
1 0
Report
Ssss Sssss
Ssss Sssss Dec 14, 2020 7:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes, bought some for $2.22
Reply
0 0
Report
David Beer
David Beer Dec 14, 2020 7:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
not looking so great now is it,
Reply
1 0
Report
Ssss Sssss
Ssss Sssss Dec 14, 2020 7:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
David Beer  sold @ 2.32. now looking to enter @ 1.66
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email